141 related articles for article (PubMed ID: 7917790)
1. Molecular cloning and functional characterization of a human liver vasoactive intestinal peptide receptor.
Gagnon AW; Aiyar N; Elshourbagy NA
Cell Signal; 1994 Mar; 6(3):321-33. PubMed ID: 7917790
[TBL] [Abstract][Full Text] [Related]
2. Human intestinal VIP receptor: cloning and functional expression of two cDNA encoding proteins with different N-terminal domains.
Couvineau A; Rouyer-Fessard C; Darmoul D; Maoret JJ; Carrero I; Ogier-Denis E; Laburthe M
Biochem Biophys Res Commun; 1994 Apr; 200(2):769-76. PubMed ID: 8179610
[TBL] [Abstract][Full Text] [Related]
3. Cloning and functional characterization of the human vasoactive intestinal peptide (VIP)-2 receptor.
Adamou JE; Aiyar N; Van Horn S; Elshourbagy NA
Biochem Biophys Res Commun; 1995 Apr; 209(2):385-92. PubMed ID: 7733904
[TBL] [Abstract][Full Text] [Related]
4. Cloning and expression of the human vasoactive intestinal peptide receptor.
Sreedharan SP; Robichon A; Peterson KE; Goetzl EJ
Proc Natl Acad Sci U S A; 1991 Jun; 88(11):4986-90. PubMed ID: 1675791
[TBL] [Abstract][Full Text] [Related]
5. The VIP2 receptor: molecular characterisation of a cDNA encoding a novel receptor for vasoactive intestinal peptide.
Lutz EM; Sheward WJ; West KM; Morrow JA; Fink G; Harmar AJ
FEBS Lett; 1993 Nov; 334(1):3-8. PubMed ID: 8224221
[TBL] [Abstract][Full Text] [Related]
6. Identification of a VIP-specific receptor in guinea pig tenia coli.
Teng BQ; Grider JR; Murthy KS
Am J Physiol Gastrointest Liver Physiol; 2001 Sep; 281(3):G718-25. PubMed ID: 11518684
[TBL] [Abstract][Full Text] [Related]
7. Molecular cloning and functional characterization of a human VIP receptor from SUP-T1 lymphoblasts.
Svoboda M; Tastenoy M; Van Rampelbergh J; Goossens JF; De Neef P; Waelbroeck M; Robberecht P
Biochem Biophys Res Commun; 1994 Dec; 205(3):1617-24. PubMed ID: 7811244
[TBL] [Abstract][Full Text] [Related]
8. Analogues of VIP, helodermin, and PACAP discriminate between rat and human VIP1 and VIP2 receptors.
Gourlet P; Vandermeers A; Van Rampelbergh J; De Neef P; Cnudde J; Waelbroeck M; Robberecht P
Ann N Y Acad Sci; 1998 Dec; 865():247-52. PubMed ID: 9928018
[TBL] [Abstract][Full Text] [Related]
9. Vasoactive intestinal polypeptide and pituitary adenylate cyclase-activating polypeptide receptor chimeras reveal domains that determine specificity of vasoactive intestinal polypeptide binding and activation.
Hashimoto H; Ogawa N; Hagihara N; Yamamoto K; Imanishi K; Nogi H; Nishino A; Fujita T; Matsuda T; Nagata S; Baba A
Mol Pharmacol; 1997 Jul; 52(1):128-35. PubMed ID: 9224822
[TBL] [Abstract][Full Text] [Related]
10. A cloned frog vasoactive intestinal polypeptide/pituitary adenylate cyclase-activating polypeptide receptor exhibits pharmacological and tissue distribution characteristics of both VPAC1 and VPAC2 receptors in mammals.
Alexandre D; Anouar Y; Jegou S; Fournier A; Vaudry H
Endocrinology; 1999 Mar; 140(3):1285-93. PubMed ID: 10067855
[TBL] [Abstract][Full Text] [Related]
11. Cloning and functional expression of a human neuroendocrine vasoactive intestinal peptide receptor.
Sreedharan SP; Patel DR; Huang JX; Goetzl EJ
Biochem Biophys Res Commun; 1993 Jun; 193(2):546-53. PubMed ID: 8390245
[TBL] [Abstract][Full Text] [Related]
12. Stable expression of the recombinant human VIP1 receptor in clonal Chinese hamster ovary cells: pharmacological, functional and molecular properties.
Gaudin P; Couvineau A; Maoret JJ; Rouyer-Fessard C; Laburthe M
Eur J Pharmacol; 1996 Apr; 302(1-3):207-14. PubMed ID: 8791009
[TBL] [Abstract][Full Text] [Related]
13. Receptors for VIP and PACAP in guinea pig cerebral cortex: effects on cyclic AMP synthesis and characterization by 125I-VIP binding.
Zawilska JB; Dejda A; Niewiadomski P; Gozes I; Nowak JZ
J Mol Neurosci; 2005; 25(3):215-24. PubMed ID: 15800375
[TBL] [Abstract][Full Text] [Related]
14. Characterization of vasoactive intestinal peptide receptors in human liver.
Rodríguez-Henche N; Rodríguez-Pena MS; Guijarro LG; Prieto JC
Biochim Biophys Acta; 1994 Mar; 1221(2):193-8. PubMed ID: 8148398
[TBL] [Abstract][Full Text] [Related]
15. Molecular evolution of vertebrate VIP receptors and functional characterization of a VIP receptor from goldfish Carassius auratus.
Chow BK; Yuen TT; Chan KW
Gen Comp Endocrinol; 1997 Feb; 105(2):176-85. PubMed ID: 9038250
[TBL] [Abstract][Full Text] [Related]
16. Characterization of vasoactive intestinal peptide/pituitary adenylate cyclase-activating peptide receptors in human benign hyperplastic prostate.
Solano RM; Carmena MJ; Carrero I; Cavallaro S; Roman F; Hueso C; Travali S; Lopez-Fraile N; Guijarro LG; Prieto JC
Endocrinology; 1996 Jul; 137(7):2815-22. PubMed ID: 8770902
[TBL] [Abstract][Full Text] [Related]
17. The C-terminal part of VIP is important for receptor binding and activation, as evidenced by chimeric constructs of VIP/secretin.
Wulff B; Møller Knudsen S; Adelhorst K; Fahrenkrug J
FEBS Lett; 1997 Aug; 413(3):405-8. PubMed ID: 9303545
[TBL] [Abstract][Full Text] [Related]
18. Receptors for vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide in turkey cerebral cortex: characterization by [125I]-VIP binding and effects on cyclic AMP synthesis.
Zawilska JB; Niewiadomski P; Nowak JZ
Gen Comp Endocrinol; 2004 Jun; 137(2):187-95. PubMed ID: 15158130
[TBL] [Abstract][Full Text] [Related]
19. Tissue specific expression of different human receptor types for pituitary adenylate cyclase activating polypeptide and vasoactive intestinal polypeptide: implications for their role in human physiology.
Wei Y; Mojsov S
J Neuroendocrinol; 1996 Nov; 8(11):811-7. PubMed ID: 8933357
[TBL] [Abstract][Full Text] [Related]
20. Human VPAC1 receptor selectivity filter. Identification of a critical domain for restricting secretin binding.
Du K; Couvineau A; Rouyer-Fessard C; Nicole P; Laburthe M
J Biol Chem; 2002 Oct; 277(40):37016-22. PubMed ID: 12133828
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
